Identified Hapten Patents (Class 436/822)
  • Patent number: 8124743
    Abstract: The present invention discloses a method of purifying bivalent antibodies or antibody fragments that are active at both Fab sites from a source of antibodies or antibody fragments using a non-chromatographic method that includes inducing the formation of cyclic immunoglobulin aggregates by addition of multivalent hapten to a salt solution of soluble antibodies or antibody fragments, wherein the multivalent hapten possesses a linker between the two haptens effective to prevent the binding of both haptens of the ligand to the same antibody or antibody fragment.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: February 28, 2012
    Assignee: President and Fellows of Harvard College
    Inventors: Vijay M. Krishnamurthy, Lara A. Estroff, Vincent Semetey, Samuel W. Thomas, George K. Kaufman, Zihni Basar Bilgicer, George M. Whitesides
  • Patent number: 7771954
    Abstract: A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof. The level of the systemic marker is compared with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: August 10, 2010
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang
  • Patent number: 7498421
    Abstract: A pharmaceutical composition comprising a compound of formula (I) wherein X is an electron withdrawing group, Y1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, —SO2R4, —CO2R4, —CONHR4 or —COR4, and each of R1, R2 and R4, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, or a compound of formula (II) wherein each of Y2 and Y3, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, —SO2R9, —CO2R9, —CONHR9 or —COR9, Z is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, —CH?C(NHR10)CH((CH2)m CO2R11)(C?O)CH3 or —CH2(C?O)CH((CH2)mCO2R11)(C?O)CH3, R8 is —(CH2)nCO2R12, each of R5 to R7 and R9 to R12, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and each of m and n, which may be the same or different, is 1 to 6 or a compound of formula (III) wherein each of Y4 to Y6, which may be the same or
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 3, 2009
    Assignee: Medical Research Council
    Inventors: Joseph Floyd Clark, Thomas Andrew Daniel Cadoux-Hudson, Christopher Joseph Schofield
  • Patent number: 7071006
    Abstract: Carriers hold remote-acting bodies which can be manipulated by a remote force, and also hold a micro-substance which is a target substance of an assay. The remote-acting bodies are manipulated in order to control the positions of the micro-substances, so as to execute assays for various target substances efficiently, at low cost, easily, and reliably. Various aspects of interest include the carriers which hold the micro-substances, a system suspending the carriers, an apparatus for manipulating the carriers, and a method of controlling the position of the carriers.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: July 4, 2006
    Assignee: Precision System Science Co., Ltd.
    Inventors: Hideji Tajima, Yoshiro Okami
  • Patent number: 6932969
    Abstract: The invention concerns a method for preparing Ig fractions from human polyvalent intravenous Immunoglobulins (IV Ig) which are in particular likely to be responsible for the immunomodulatory effect observed during the treatment of certain autoimmune diseases. The invention concerns Ig fractions having reactivity to IgM, IgG F(ab?)2 or DNP hapten and no or little reactivity to non-self antigens, that is Ig fractions which have idiotypic interactions among themselves (connected fraction) or which include natural antibodies reacting with the DNP hapten. Said fractions exhibit a polyreactivity to specific autoantigens.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: August 23, 2005
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Dominique Bourel, Martine Bruley-Rosset, Frédéric Dhainaut, Jacky Lirochon
  • Patent number: 6927035
    Abstract: A monoclonal antibody which reacts strongly with uracil and thymine but scarcely with N-carbamyl-?-alanine; a hybridoma producing this monoclonal antibody; a method of immunochemically assaying uracil or thymine characterized by using the above-described monoclonal antibody; and diagnostics for DPD deficiency containing the above monoclonal antibody. Because of high sensitivity and specific reaction with uracil and thymine, the above-described monoclonal antibody enables convenient, quick, and selective assaying of uracil and thymine in a sample. The antibody is useful in screening patients with DPD deficient cancer with contraindication to the administration of pyrimidine fluoride-based antitumor agents.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: August 9, 2005
    Assignees: Taiho Pharmaceutical Co., LTD, Biomedical Research Group Inc.
    Inventor: Gen-ichiro Soma
  • Patent number: 6727072
    Abstract: A kit containing the reagents necessary for the qualitative or quantitative demonstration of epidermal growth factor receptor (EGFR) in formalin-fixed, paraffin-embedded tissue sections. A immunohistochemical staining procedure is employed which utilizes a primary monoclonal mouse antibody that selectively binds to EGFR. The primary antibodies bound to tissue antigens are detected using a peroxidase labeled polymer that is conjugated with secondary anti-mouse immunoglobulin antibodies. The enzymatic conversion of the subsequently applied chromogen results in formation of a visible reaction product at the site of the EGFR antigen. Following development of the chromogen, specimens may then be counterstained and coverslipped. Results are interpreted using a light microscope or other optical imaging device. The detection system is adapted for both manual and automated staining.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: April 27, 2004
    Assignee: Dako Corporation
    Inventors: Elizabeth O. Spaulding, Marc E. Key
  • Patent number: 6670196
    Abstract: The invention relates in part to novel methods of rapidly determining the ratio of biological molecules. The invention also relates in part to a kit for rapidly determining the ratio of biological molecules.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: December 30, 2003
    Assignee: Biosite, Inc.
    Inventor: Kenneth F. Buechler
  • Publication number: 20030113794
    Abstract: A particle-enhanced assay for determining an analyte in a test sample in which an additive for reducing non-specific particle aggregation is added in an amount to substantially reduce non-specific aggregation.
    Type: Application
    Filed: December 7, 2001
    Publication date: June 19, 2003
    Inventors: Kurt L. Brillhart, Julie A. Whiteside
  • Patent number: 6548306
    Abstract: The full amino acid and DNA sequences of placental protein 13 (PP13) are disclosed. Also described are various PP13 derived peptide fragments, and a recombinant method for the production of PP13. PP13 may be used in a screening and a diagnostic method for pregnancy-related complications.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: April 15, 2003
    Assignee: Diagnostic Technologies Ltd.
    Inventors: Arie Admon, Yoav Paltieli, Ronit Slotky, Silvia Mandel
  • Patent number: 6309646
    Abstract: A method is disclosed for producing a soluble conjugate vaccine, and preferably protein/polysaccharide conjugates. In this process, the polysaccharide is reacted with a reagent so as to provide a functional group on the polysaccharide molecule. Once the functional group is in place, the polysaccharide is reacted with a homobifunctional or heterobifunctional vinylsulfone to produce a vinylsulfone derivatized polysaccharide. Thereafter, the vinylsulfone derivatized polysaccharide is reacted with a protein to produce the conjugate. If desired, the protein may be derivatized with a functional group prior to the conjugation reaction step. In an alternative embodiment, the protein may be functionalized with a reactive group and then derivatized with the vinylsulfone group to produce a vinylsulfone derivatized protein. This protein may then be reacted with a polysaccharide to produce the conjugate. Optionally, the polysaccharide may be functionalized with a reactive group prior to the conjugation reaction.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: October 30, 2001
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventor: Andrew Lees
  • Patent number: 6204005
    Abstract: The present invention provides a method for determining qualitatively or quantitatively the presence of toxic congeners of polychlorinated biphenyl in a test sample. The method includes the steps of: providing a known quantity of antibodies to the toxic polychlorinated biphenyl congener; providing a competitor that will bind to said antibodies in competition with the toxic polychlorinated biphenyl congener and having a lower affinity to said antibodies than said antibodies have to the toxic polychlorinated biphenyl congener; incubating said antibodies and said competitor in the presence of a test sample; and detecting the presence of the toxic polychlorinated biphenyl toxic congener in the test sample.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: March 20, 2001
    Assignee: Ecochem Research, Inc.
    Inventors: Robert E. Carlson, Todd A. Swanson
  • Patent number: 6190921
    Abstract: The invention deals with the use of a reactive compound in immunological analyses. The compound is ouabain or its analog to which another compound, labeled by radioiodine or by a fluorogen, is coupled. The invention covers also the method to measure ouabain or its analog in plasma to diagnose cardiovascular and endocrine diseases and other harmful conditions.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: February 20, 2001
    Inventors: Pekka Juhani Leppäluoto, Lauri Erkki Olli Vakkuri, Olli Jaakko Vuolteenaho
  • Patent number: 6068981
    Abstract: A method of monitoring a therapeutic regimen in an animal, the method involving a) providing to the animal a therapeutic compound and a detectable compound that passes into the bloodstream, excretory system, or other tissue or body fluid in detectable form; b) after a period of time, following step (a), sufficient for passage of a detectable amount of the detectable compound into the body fluid or tissue, collecting a sample of the fluid or tissue from the animal; and c) measuring or detecting the detectable compound, or a detectable metabolite thereof, in the sample, wherein the detectable compound involves one member of a specific binding pair, and detection is carried out using the second member of the specific binding pair.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: May 30, 2000
    Assignee: Biocode, Inc.
    Inventors: James H. Rittenburg, Frank G. Angella, Michael G. Pappas
  • Patent number: 5942442
    Abstract: Apparatus and method for detection of low levels of about 1 ppb of analyte in samples using an enclosed permeable membrane enrichment device and agglutination reaction slide test apparatus.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: August 24, 1999
    Assignees: The Perkin-Elmer Corporation, Roche Dianostic Systems, Inc.
    Inventors: Joseph L. Di Cesare, Steven M. Rosen
  • Patent number: 5869348
    Abstract: In accordance with the present invention, ELISA methods for the measurement of NO levels in mammalian body fluids utilizing monoclonal antibodies directed against dithiocarbamates and related iron complexes are described. It has been found that conjugation of dithiocarbamates to a macromolecule produces immunogenic dithiocarbamate-macromolecule derivatives. Such derivatives can be used for the production (e.g., in rodents) of monoclonal antibodies directed against different forms of dithiocarbamates (e.g., free dithiocarbamates, as well as complexes thereof with iron and, optionally, nitric oxide). In contrast, non-derivatized dithiocarbamates alone are not immunogenic. The simple, easy and non-invasive ELISA methods for measurement of NO levels in body fluids will find a variety of uses, e.g., for diagnosis and monitoring of NO overproduction that has been associated with many inflammatory and infectious diseases.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: February 9, 1999
    Assignee: Medinox, Inc.
    Inventor: Ching-San Lai
  • Patent number: 5851781
    Abstract: The present invention discloses novel immunogens, antibodies prepared from such immunogens, and labeled reagents useful in immunoassays for the detection and quantification of testosterone in a test sample. Also disclosed are immunoassays using these reagents and methods for synthesizing these reagents. The immunoassays are preferably microparticle enzyme immunoassays (MEIAs) and fluorescence polarization immunoassays (FPIAs). Further disclosed are novel starting materials for making the above novel immunogens and labeled reagents. Methods for making the novel immunogens and labeled reagents from the novel starting materials are also disclosed.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: December 22, 1998
    Assignee: Abbott Laboratories
    Inventors: Maciej Adamczyk, Yon-Yih Chen, John A. Walling, Bryan D. James, Sharon G. Artrip
  • Patent number: 5840588
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment or both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine, by active immunization and also passive immunization.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 24, 1998
    Inventor: Meir Strahilevitz
  • Patent number: 5811246
    Abstract: The invention relates to a process for immobilization onto the surface of enzyme linked immunosorbent assay (ELISA) plates of a compound or for immunization with a compound, wherein said compound is in the form of a compound carrier complex which is either an avidin-biotinyl compound complex or a streptavidin-biotinyl compound complex.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: September 22, 1998
    Assignee: The Research Foundation of State University of New York
    Inventors: Kalyan R. Anumula, Nathan N. Back
  • Patent number: 5780319
    Abstract: Liposome reagents used in assays to detect the presence or amount of an analyte in a test sample, particularly where the analyte is antiphospholipid antibodies are described. The liposome reagents comprise a liposome, a ligand chosen to bind specifically with the analyte and associated with the liposome membrane, and a haptenated component associated with the membrane of the liposome where the hapten is chosen to bind specifically to a receptor bound to a solid phase or to a label compound that is an element of a signal detection system and where the liposome reagent is prepared so that during the assay the linkage between the solid phase and ligand of the liposome reagent is maintained.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: July 14, 1998
    Assignee: Pasteur Sanofi Diagnostics
    Inventors: Nancy Maxfield Wilson, Catherine Larue
  • Patent number: 5776713
    Abstract: In general, the invention features a method of marking a product for identification in which a marker, composed of a low molecular weight hapten covalently bound to a compound, is associated with the product. Where the marker is non-deleterious to the product, inert with respect to the product, and not already associated with the product. The invention also features hapten markers produced by covalently binding a hapten to a functional monomer and subsequently polymerizing the hapten-labeled monomer to form a hapten-labeled polymer.
    Type: Grant
    Filed: August 16, 1994
    Date of Patent: July 7, 1998
    Assignee: Biocode Ltd.
    Inventors: Ronald Colin Garner, David J. Phillips, Timothy G. Wilkinson, Frank G. Angella, Erwin R. Dorland, Martin W. Stow
  • Patent number: 5770390
    Abstract: Lipohaptens of the general formula I(X).sub.m --R--Y--(S).sub.n --P (I)whereinR is a hydrocarbyl backbone having from 2 to 30 carbon atomsX is a hydrocarbyl radical having from 6 to 30 carbon atoms, which is linked to R via a bonding group containing one or more heteroatomsm is an integer from 1 to 5P is a polypeptide or polysaccharide residue having from 2 to 100 aminoacid or glycosyl unitsY is a functional group capable of binding to a free amino group of the polypeptide P or a carboxy, hemiacetal or hydroxy group of the polysaccharide PS is a difunctional spacer group, the functional groups thereof being capable of binding with the functional groupY on the one hand and a free amino, carboxy or hydroxy group of the polypeptide or polysaccaride P on the other hand, andn is 0 or 1and their use in immunoreactions for determining antibodies and antigens, respectively.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: June 23, 1998
    Assignee: Dade International Inc.
    Inventor: Wilhelm Stoffel
  • Patent number: 5686253
    Abstract: A method is disclosed for stabilizing a conjugate of an enzyme and a member of a specific binding pair (enzyme conjugate). The method comprises the step of combining the enzyme conjugate with an effective amount of an antibody for the enzyme where the antibody does not substantially inhibit the activity of the enzyme. The invention has application to assays for the determination of an analyte wherein enzyme conjugates are employed. The improvement comprises employing as a reagent in the assay an immune complex of an enzyme conjugate and an antibody for the enzyme where the antibody does not substantially inhibit the activity of the enzyme. Compositions comprising such an immune complex and kits comprising such an immune complex in packaged combination with other assay reagents are also disclosed.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: November 11, 1997
    Assignee: Behringwerke AG
    Inventors: Carl N. Skold, Margaret Henson, Thomas Michael Houts, Ian Gibbons
  • Patent number: 5674753
    Abstract: Diagnostic/prognostic methods are provided for detecting and/or quantitating in the body fluids, preferably serum, of mammals carrying a malignant tumor burden, elevated levels of a portion of the epidermal growth factor receptor (EGFr) which comprises substantially the EGFr ectodomain having a molecular weight in the range of from about 90 kilodaltons (kd) to about 115 kd, preferably from about 95 kd to about 105 kd, and more preferably about 100 kd. Substantially pure compositions comprising EGFr ectodoman protein and/or fragments thereof are disclosed as well as test kits for performing the disclosed assays.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: October 7, 1997
    Assignee: Chiron Diagnostics Corporation
    Inventors: Jeanne P. Harvey, Victoria A. Crebbin, Roger P. Walker, Victor Liu, Susan L. Hammond, Patricia A. McDonald
  • Patent number: 5656447
    Abstract: Polyclonal antibodies which are specific against quinolinic acid are provided. The antibodies are used for immunohistological detection of quinolinic acid.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: August 12, 1997
    Assignee: Georgetown University
    Inventors: M. A. Aryan Namboodiri, John R. Moffett
  • Patent number: 5643732
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment or both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine by active immunization and also passive immunization.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 1, 1997
    Inventor: Meir Strahilevitz
  • Patent number: 5641690
    Abstract: A method is described for determining a hapten which method comprises (i) contacting the hapten with a binding partner of the hapten, whereby the hapten becomes bound to some of the binding partner, (ii) contacting the unbound binding partner with a secondary binding partner therefor, (iii) contacting the binding partner with an antibody which binds the binding partner which has bound thereto the hapten but which does not bind the binding partner which has bound thereto its secondary binding partner; and (iv) determining the amount of antibody bound to the binding partner. Kits for use in the method are also described.
    Type: Grant
    Filed: November 20, 1995
    Date of Patent: June 24, 1997
    Assignee: Cambridge Patent Developments Limited
    Inventor: Colin Henry Self
  • Patent number: 5631138
    Abstract: A method for the measurement of serum bile acids by ELISA comprising: preparing a bile acid active ester, reacting the ester with a bovine serum albumin solution, dialyzing, and immunizing a mammal other than human being with the dialyzate thus obtained as an antigen to thereby give an anti-bile acid antibody; reacting said active ester with an enzyme to thereby prepare an enzyme-labeled bile acid as an enzyme-labeled antigen; to a secondary antibody-coated plate, adding a dilution of the serum to be assayed, an anti-bile acid antibody solution and an enzyme-labeled antigen solution and reacting these substances followed by the addition of a substrate and the reaction therewith; measuring the absorbance of the reaction mixture and determining the concentration of each bile acid on the basis of the standard curve measured simultaneously; and referring the sum of the concentrations of these bile acids to the total bile acid concentration; and a method for the diagnosis of a liver disease comprising: calculating
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: May 20, 1997
    Assignee: Yuugengaisha B.S.R.
    Inventors: Motonari Kano, Masaru Matsumoto
  • Patent number: 5616503
    Abstract: A method of determining a hapten which comprises: (1) contacting the sample which contains or may contain the hapten with a first binding partner which binds the hapten; (2) separating the hapten bound to the first binding partner from material which is not bound by the first binding partner; (3) contacting the hapten bound to the first binding partner with a second binding partner which binds the hapten; and (4) assaying the hapten bound to a binding partner as is described. Kits are also described.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: April 1, 1997
    Inventor: Colin H. Self
  • Patent number: 5616505
    Abstract: Novel tethered hapten intermediates and related conjugates based on 3-phenyl-1-adamantaneacetic acid, as well as methods for making and using such conjugates. Haptens based on the above core structure may be substituted at any position on the phenyl ring, especially at the para position. Using tethered intermediates, immunogens, tracers, solid supports and labeled oligonucleotides are all described; as are methods for using the intermediates to prepare the conjugates, methods of using the conjugates to make and purify anitbodies, as assay tracers, and in nucleic acid hybridization assays. Kits containing haptenated oligonucleotides and anti-hapten conjugates are also described.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: April 1, 1997
    Assignee: Abbott Laboratories
    Inventor: Philip G. Mattingly
  • Patent number: 5614419
    Abstract: Immunoassay methods and reagents for the specific quantification of amitriptyline or nortriptyline in a test sample are disclosed employing antibodies prepared with amitriptyline or nortriptyline derivatives of the Formula III: ##STR1## wherein for amitriptyline, R is CH.sub.3, and for nortriptyline, R is H. The present invention also describes the synthesis of unique fluorescein tracers of the structure of Formula IV and Formula V: ##STR2## wherein for a specific amitriptyline immunoassay, W.sub.1 is a heteroatom linked to the aromatic ring at the 2 or 3 position, and for a specific nortriptyline immunoassay, W.sub.2 is two heteroatoms linked together and attached to the aromatic ring at the 2 or 3 position, and wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: March 25, 1997
    Assignee: Abbott Laboratories
    Inventors: Maciej Adamczyk, Jeffrey R. Fishpaugh, Donald Johnson, Daryl E. Hartter
  • Patent number: 5607862
    Abstract: A method for assaying bone resorption rates which consists of quantitating the concentration of peptide fragments derived from bone collagen, found in a body fluid is disclosed. The method includes immunometric assay, fluorometric assay and electrochemical titration. The structure of specific peptide fragments having 3-hydroxypyridinium cross-links found in urine of Paget's disease patients and procedures for making monoclonal antibodies is described.
    Type: Grant
    Filed: June 21, 1995
    Date of Patent: March 4, 1997
    Assignee: Washington Research Foundation
    Inventor: David R. Eyre
  • Patent number: 5580741
    Abstract: A sensitive chemiluminescence immunoassay method for field detection of the presence or the amount of low chlorinated biphenyl compounds in a solution is disclosed. The assay has a five minute analysis time and a working range of detection as low as about 1 part per billion chlorinated biphenyl. Kits for the detection of chlorinated biphenyls are disclosed.
    Type: Grant
    Filed: June 29, 1994
    Date of Patent: December 3, 1996
    Assignee: General Electric Company
    Inventors: John Y. Gui, Donald R. Berdahl, Emily Y. Shu, Joseph J. Salvo, Sandra F. Feldman
  • Patent number: 5580742
    Abstract: For the detection of proteins containing phosphorylated tyrosine the sample of a body fluid is incubated with at least two receptors R.sub.1 and R.sub.2 whereby a change in signal is produced by binding of at least the receptors R.sub.1 and R.sub.2 with the substance to be detected in the sample solution and in which in each case one of the two receptors contains an antibody or its derivative capable of specifically binding to the protein to be detected and the other receptor contains an antibody or its derivative capable of specifically binding to phosphorylated tyrosine and the signal change caused by the binding is determined in the sample.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: December 3, 1996
    Assignee: Boehringer Mannheim GmbH
    Inventors: Heinz Bodenm uller, Andreas Dessauer
  • Patent number: 5573955
    Abstract: A method for reducing or eliminating tyramine interference from amphetamine and methamphetamine immunoassays, comprising treating the sample with aqueous tyramine oxidase for a time and at a temperature and pH sufficient to deaminate any tyramine present in the sample, is provided.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 12, 1996
    Assignee: Microgenics Corp.
    Inventors: Pyare Khanna, Theresa Medlin
  • Patent number: 5565326
    Abstract: Specific binding ligands can be detected with an assay which utilizes an immobilized receptor for the ligand, a reporter enzyme, an inhibitor antibody and an anti-inhibitor antibody. Both antibodies are specific for the reporter enzyme. The inhibitor antibody effectively shuts down the activity of the reporter enzyme when it is complexed thereto. The anti-inhibitor antibody binds to the reporter enzyme, does not affect the enzymatic activity, but prevents the binding of the inhibitor enzyme. This assay provides a direct correlation of the target specific binding ligand to the signal generated without the use of separation or wash steps.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: October 15, 1996
    Assignee: Johnson & Johnson Clinical Diagnostics, Inc.
    Inventors: John L. Daiss, Kevin M. Gorman, Carolyn R. Hinchman
  • Patent number: 5538852
    Abstract: A method for determining qualitatively or quantitatively the presence of polychlorinated biphenyl in a test sample. The method includes the steps of: providing a known quantity of antibodies to polychlorinated biphenyl; providing a competitor that will bind to said antibodies in competition with polychlorinated biphenyl and having a lower affinity to said antibodies than said antibodies have to polychlorinated biphenyl; incubating said antibodies and said competitor in the presence of a test sample; and detecting the presence of polychlorinated biphenyl in the test sample. The competitor used in this method has one of the following structures: ##STR1## wherein A is selected from the group consisting of --NH--, --S--, --O--, --CH.sub.2 --, --NH--C(O)--, --C(O)--NH--, --NH--C(O)--NH--, --NH--C(S)--NH--, --N(CH.sub.3)--, --N(CH.sub.3).sub.2 --, and --O--C(S)--NH--; B is preferably a single bond or an organic or inorganic group; C is selected from the group consisting of --CO.sub.2 H, --NH.sub.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: July 23, 1996
    Assignee: Ecochem Research, Inc.
    Inventors: Robert E. Carlson, Todd A. Swanson
  • Patent number: 5527711
    Abstract: A method is provided for detecting an analyte of interest in a sample. The method involves binding the analyte to the surface of a substrate through a biotin-biotin binding protein interaction, contacting the surface-bound analyte with a quantitatively detectable analyte-binding moiety that binds thereto, measuring the quantity of detectable moiety bound to the substrate surface and deriving therefrom the quantity of analyte in solution. A preferred use for the present method is in conjunction with a piezoelectric surface transverse wave device. Novel reagents useful for carrying out the inventive method are provided as well.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: June 18, 1996
    Assignee: Hewlett Packard Company
    Inventors: May Tom-Moy, Joel Myerson, Karla M. Robotti
  • Patent number: 5525526
    Abstract: Antibodies raised against derivatives of inositol are used to assay for specific isomers of inositol in a sample by first converting any inositol present in the sample to the derivative that was used to raise the antibody and then conducting an immunoassay for the inositol derivative in a conventional manner.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: June 11, 1996
    Assignee: The University of Virginia Patent Foundation
    Inventors: Joel Linden, Thomas Piccariello, George Vandenhoff
  • Patent number: 5525524
    Abstract: Assay for detecting the amount or presence of target ligand in a sample. The assay includes a ligand analogue conjugate having a linkage site and a binding site, a ligand receptor, and a sample. The assay includes the steps of providing at least one crosstalk inhibitor. This inhibitor, under assay conditions, competes with the linkage site of the ligand analogue conjugate for binding to the ligand receptor, and does not compete with the binding site of the ligand analogue conjugate for binding to the ligand receptor. In the invention, the assay is performed for the target ligand in the presence of a sufficient amount of the crosstalk inhibitor to reduce the amount of binding of the linkage site of the ligand analogue conjugate to the ligand receptor. The invention also features a method for identifying crosstalk inhibitors, and the crosstalk inhibitors themselves.
    Type: Grant
    Filed: August 3, 1993
    Date of Patent: June 11, 1996
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Richard R. Anderson, Theodore T. Lee, Gunars E. Valkirs
  • Patent number: 5518887
    Abstract: The present invention relates to immunoassay methods for detecting and measuring the amount of an analyte in a sample by means of generic anti-hapten antibodies. Also disclosed are multi-analyte immunoassay methods. Reagents, devices, and kits using the anti-hapten antibodies are also disclosed. The present invention also relates to immunoassay methods for detecting and measuring the amount of an analyte in a sample by means of a dual antibody format.The present invention also relates to dyed erythrocytes, preferably fixed, which are coated with antibodies. Also disclosed is the use of these dyed erythrocytes in agglutination assays to detect and measure the presence of an analyte in a sample. The analyte can be a hapten, an antigen, or an antibody. Also included are agglutination assays, compositions and kits using these dyed and coated erythrocytes.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: May 21, 1996
    Assignee: Abbott Laboratories
    Inventors: Robert G. Parsons, Robert Kowal
  • Patent number: 5501985
    Abstract: Assay reagents, devices, methods and kits used in the analysis of low molecular weight analytes which by themselves are too small or unable to bind to two specific binding members at the same time. The invention involves the use of an analyte-substitute reagent (ASR) comprising at least two components, the first of which is identical to or an analog of the analyte to be determined, while the second is an unrelated ligand for which an antibody or other specific binding member can be obtained or produced.
    Type: Grant
    Filed: April 21, 1994
    Date of Patent: March 26, 1996
    Assignee: Abbott Laboratories
    Inventors: Bennett W. Baugher, Aurora J. Chamberlain, Sharon M. Devereaux, Frank S. Ungemach
  • Patent number: 5492839
    Abstract: Disclosed is a novel photo-activatable derivative of ryanodine 9-hydroxy-21-(4-azidobenzoyloxy)-9-epiryanodine. This novel ryanodine derivative has been conjugated to keyhole limpet hemocyanin (KLH) and used for the production of antibodies with high affinity and specificity to ryanodine. A radioimmunoassay specific for ryanodine was developed using the anti-ryanodine antibodies, and a dissociation constant for ryanodine of 1 nM was determined. Also disclosed is the binding of a labeled, photoactivatable derivative of ryanodine (ABRy) with the ryanodine receptor of skeletal, cardiac and brain membranes. Digestion of the labeled ryanodine receptor revealed a labeled 76 kDa tryptic fragment which is critical for the formation of the high affinity ryanodine binding site.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: February 20, 1996
    Assignee: University of Iowa Research Foundation
    Inventors: Kevin P. Campbell, Derrick R. Witcher, Peter McPherson, Steven D. Kahl, John D. Windass, Terence Lewis, Philip Bentley
  • Patent number: 5486479
    Abstract: The invention relates to immunoassay reagents that are both sensitive and specific and which require no sample pretreatment. The invention reagents are particularly useful for assaying digoxin concentrations in patient sera. More particularly, the invention relates to methods and kits comprising (A) an immunoreactant immobilized on a support; and, (B) a buffer agent comprising (i) a buffering agent, (ii) sodium chloride, (iii) choline chloride, (iv) a polysaccharide, (v) fatty-acid-free serum albumin, and (vi) a non-specific reaction suppressor of the formula: ##STR1## wherein X is --NH--(CO)--NH--, --NH--(CS)--NH--, or --N.dbd.C.dbd.N--, R.sub.1 and R.sub.2, which may be the same or different, are C.sub.1 -C.sub.5 linear or branched alkyl groups, or R.sub.1 and R.sub.2, together with nitrogen, is ##STR2## or the metho-p-toluenesulfonate salt thereof, Y, which may be the same or different, is any of H, OH and halogen,R.sub.3 is --NR.sub.1 R.sub.2, --NH.sub.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: January 23, 1996
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Michio Ito, Satoshi Sugawa, Atsushi Yanagida
  • Patent number: 5476770
    Abstract: The invention relates to a process for the immunometric determination of an antigen or hapten.According to this process, contacting takes place (FIG. 1A) between the antigen or hapten (3) to be determined and the antibodies (2) fixed to a solid phase in order to immunologically bond the antigen or hapten with the antibody. This is followed (FIG. 1B) by immobilizing the antigen or hapten (3) by a covalent bond (4) to the solid phase (1) whilst releasing its epitope (FIG. 1C). This is followed by the contacting thereof (FIG. 1D) with labelled antibodies (5) and determination takes place (FIG. 1E) of the quantity of fixed labelled antibodies in order to deduce therefrom the initial hapten or antigen concentration.As a result of this stage of immobilizing and releasing the epitope, a high sensitivity is obtained using a single antibody.
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: December 19, 1995
    Assignee: Commissariat A L'Energie Atomique
    Inventor: Philippe Pradelles
  • Patent number: 5468651
    Abstract: A method is described for determining a hapten which method comprises (i) contacting the hapten with a binding partner of the hapten, whereby the hapten becomes bound to some of the binding partner, (ii) contacting the unbound binding partner with a secondary binding partner therefor, (iii) contacting the binding partner with an antibody which binds the binding partner which has bound thereto the hapten but which does not bind the binding partner which has bound thereto its secondary binding partner; and (iv) determining the amount of antibody bound to the binding partner. Kits for use in the method are also described.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: November 21, 1995
    Assignee: Cambridge Patent Developments Limited
    Inventor: Colin H. Self
  • Patent number: 5439798
    Abstract: Novel derivatives of procainamide and N-acetylprocainamide (NAPA) are disclosed having the following formula: ##STR1## wherein: X=hydrogen or acetyl;R.sub.1 =an alkyl group having 1 to 3 carbon atoms;m=an integer from 2 to 10;R.sub.2 =an alkyl, cycloalkyl or aryl group having 2 to 10 carbon atoms;Z=a poly(amino acid); andn=1 to p where p=MW of Z/1000.The derivatives include maleimide conjugates of proteins or poly(amino acids), enzymes, enzyme donor polypeptides and labeling substances. Novel activated hapten intermediates useful in the preparation of the conjugates and methods for synthesis of the hapten intermediates and derivatives are also disclosed.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: August 8, 1995
    Assignee: Boehringer Mannheim Corporation
    Inventors: Gerald F. Sigler, Charles F. Walter, Charles E. Durant, Todd Glancy, Frank E. Klein, Allan R. Dorn
  • Patent number: 5429952
    Abstract: In general, the invention features a method of marking a product for identification in which a low molecular weight hapten is associated with the product as a marker, where the hapten is non-deleterious to the product, inert with respect to the product, and not already associated with the product.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: July 4, 1995
    Assignee: Biocode, Inc.
    Inventors: Ronald C. Garner, Carl N. Martin, Michael J. Wraith, David W. Britton
  • Patent number: 5420010
    Abstract: N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the assay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured. The assays are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: May 30, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, William K. Hagmann, William A. Hanlon, John L. Humes, Wilson B. Knight, Malcolm MacCoss, Richard A. Mumford, Shrenik K. Shah
  • Patent number: 5399672
    Abstract: The invention relates to a novel process for preparing immunoconjugates consisting of haptens which are sparingly soluble or insoluble in aqueous solution and proteins/polypeptides using special solvents, in particular diethylene glycol monoalkyl ethers.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: March 21, 1995
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Mohammad Jalalian, Arnulf Heubner, Bernd Reckmann